美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Aegerion製藥

1.97

+0.0000

成交量：- -

成交額：- -

市值：5,820.38萬

市盈率：-0.33

高：1.97

開：1.97

低：1.97

收：1.97

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

Aegerion製藥

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.aegerion.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Aegerion Pharmaceuticals, Inc.是一家生物製藥公司,致力於為那些衰弱的、患有致命罕見疾病的人開發新奇的，並且能夠挽救生命的治療方法並將其用於商業用途。公司的第一個產品JUXTAPID，在2012年12月21日得到了美國食品和藥物管理局的營銷批准，並作為對低脂肪飲食和其他降脂治療的補充，包括低密度脂蛋白(LDL)血清法，如果可用，可降低純合子家族性高膽固醇血症患者(HoFH)的低密度脂蛋白膽固醇(低密度)、總膽固醇(TC)、載脂蛋白B(B朊)和非高密度脂蛋白膽固醇(non-HDL-C)。2013年1月底，該公司在美國推出了JUXTAPID。在2012年的第一季度,它向歐洲藥品局(EMA)提交了營銷授權申請(MAA)請求批准上市，作為低脂肪飲食和其他降脂治療的輔助，在用或是不用血清法的條件下減少患有血症的成年人體內的低密度脂蛋白、TC、載脂蛋白B和甘油三酯(TG)。公司於2005年2月在特拉華州法律下成立。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/AEGR/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AEGR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AEGR\",,,,,undefined,":{"symbol":"AEGR","market":"US","secType":"STK","nameCN":"Aegerion製藥","latestPrice":1.97,"timestamp":1480539600000,"preClose":1.97,"halted":0,"volume":0,"delay":0,"floatShares":14289727,"shares":29545088,"eps":-5.97,"marketStatus":"休市中","change":0,"latestTime":"11-30 16:00:00 EST","open":1.97,"high":1.97,"low":1.97,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.97,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1746432000000},"marketStatusCode":7,"adr":0,"listingDate":1287720000000,"exchange":"NASDAQ","adjPreClose":1.97,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AEGR\",,,,,undefined,":{"symbol":"AEGR","floatShares":14289727,"roa":"--","roe":"--","lyrEps":0,"shares":29545088,"dividePrice":0,"high":1.97,"amplitude":0,"preClose":1.97,"low":1.97,"week52Low":1.23,"pbRate":"--","week52High":10.85,"institutionHeld":0,"latestPrice":1.97,"eps":-5.97,"divideRate":0,"volume":0,"delay":0,"ttmEps":-5.97,"open":1.97,"prevYearClose":1.97},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.aegerion.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0293},{"period":"1month","weight":0.004},{"period":"3month","weight":-0.0583},{"period":"6month","weight":-0.0075},{"period":"1year","weight":0.1222},{"period":"ytd","weight":-0.033}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Aegerion Pharmaceuticals, Inc.是一家生物製藥公司,致力於為那些衰弱的、患有致命罕見疾病的人開發新奇的，並且能夠挽救生命的治療方法並將其用於商業用途。公司的第一個產品JUXTAPID，在2012年12月21日得到了美國食品和藥物管理局的營銷批准，並作為對低脂肪飲食和其他降脂治療的補充，包括低密度脂蛋白(LDL)血清法，如果可用，可降低純合子家族性高膽固醇血症患者(HoFH)的低密度脂蛋白膽固醇(低密度)、總膽固醇(TC)、載脂蛋白B(B朊)和非高密度脂蛋白膽固醇(non-HDL-C)。2013年1月底，該公司在美國推出了JUXTAPID。在2012年的第一季度,它向歐洲藥品局(EMA)提交了營銷授權申請(MAA)請求批准上市，作為低脂肪飲食和其他降脂治療的輔助，在用或是不用血清法的條件下減少患有血症的成年人體內的低密度脂蛋白、TC、載脂蛋白B和甘油三酯(TG)。公司於2005年2月在特拉華州法律下成立。","exchange":"NASDAQ","name":"Aegerion製藥","nameEN":"Aegerion Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"AEGR\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AEGR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2016-11-03","symbol":"AEGR","fiscalQuarterEnding":null,"expectedEps":-0.67,"name":null,"time":"","type":"earning","dateTimestamp":1478145600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2016-08-09","symbol":"AEGR","fiscalQuarterEnding":null,"expectedEps":-0.25,"name":null,"time":"","type":"earning","dateTimestamp":1470715200000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2016-05-16","symbol":"AEGR","fiscalQuarterEnding":null,"expectedEps":-1.85,"name":null,"time":"盤後","type":"earning","dateTimestamp":1463371200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2016-02-25","symbol":"AEGR","fiscalQuarterEnding":null,"expectedEps":-0.97,"name":null,"time":"盤後","type":"earning","dateTimestamp":1456376400000,"reportTimeType":"post","actualEps":-0.89},{"market":"US","date":"2015-11-09","symbol":"AEGR","fiscalQuarterEnding":null,"expectedEps":-0.51,"name":null,"time":"盤後","type":"earning","dateTimestamp":1447045200000,"reportTimeType":"post","actualEps":0.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AEGR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AEGR\",market:\"US\",delay:false,,,undefined,":{}}}